WO2003047533A2 - Composition for treating the surface of the skin - Google Patents
Composition for treating the surface of the skin Download PDFInfo
- Publication number
- WO2003047533A2 WO2003047533A2 PCT/DE2002/004372 DE0204372W WO03047533A2 WO 2003047533 A2 WO2003047533 A2 WO 2003047533A2 DE 0204372 W DE0204372 W DE 0204372W WO 03047533 A2 WO03047533 A2 WO 03047533A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition according
- skin
- mixture
- microorganisms
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 96
- 244000005700 microbiome Species 0.000 claims abstract description 30
- 241000894006 Bacteria Species 0.000 claims abstract description 22
- 229920002101 Chitin Polymers 0.000 claims abstract description 12
- 150000004676 glycans Chemical class 0.000 claims abstract description 12
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 12
- 239000005017 polysaccharide Substances 0.000 claims abstract description 12
- 239000007864 aqueous solution Substances 0.000 claims abstract description 5
- 108090000790 Enzymes Proteins 0.000 claims description 15
- 102000004190 Enzymes Human genes 0.000 claims description 15
- 229940088598 enzyme Drugs 0.000 claims description 14
- 230000000243 photosynthetic effect Effects 0.000 claims description 12
- 239000003504 photosensitizing agent Substances 0.000 claims description 11
- 208000003251 Pruritus Diseases 0.000 claims description 9
- 230000007803 itching Effects 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 239000004365 Protease Substances 0.000 claims description 6
- 239000012676 herbal extract Substances 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 150000002739 metals Chemical class 0.000 claims description 5
- 108010003118 Bacteriochlorophylls Proteins 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 208000001840 Dandruff Diseases 0.000 claims description 4
- 241000607565 Photobacterium phosphoreum Species 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- DSJXIQQMORJERS-AGGZHOMASA-M bacteriochlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC([C@H](CC)[C@H]3C)=[N+]4C3=CC3=C(C(C)=O)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 DSJXIQQMORJERS-AGGZHOMASA-M 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 238000004381 surface treatment Methods 0.000 claims description 4
- 241000192700 Cyanobacteria Species 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 241000192142 Proteobacteria Species 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 150000001340 alkali metals Chemical class 0.000 claims description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 3
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 3
- 230000002538 fungal effect Effects 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 235000021317 phosphate Nutrition 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 239000011573 trace mineral Substances 0.000 claims description 3
- 235000013619 trace mineral Nutrition 0.000 claims description 3
- 241000607620 Aliivibrio fischeri Species 0.000 claims description 2
- 244000099147 Ananas comosus Species 0.000 claims description 2
- 235000007119 Ananas comosus Nutrition 0.000 claims description 2
- 235000018185 Betula X alpestris Nutrition 0.000 claims description 2
- 235000018212 Betula X uliginosa Nutrition 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 2
- 108010004032 Bromelains Proteins 0.000 claims description 2
- 240000006432 Carica papaya Species 0.000 claims description 2
- 235000009467 Carica papaya Nutrition 0.000 claims description 2
- 241000191368 Chlorobi Species 0.000 claims description 2
- 108090000317 Chymotrypsin Proteins 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 2
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 2
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 2
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 2
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 2
- 240000000171 Crataegus monogyna Species 0.000 claims description 2
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 2
- 206010013786 Dry skin Diseases 0.000 claims description 2
- 208000010201 Exanthema Diseases 0.000 claims description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 2
- 235000003805 Musa ABB Group Nutrition 0.000 claims description 2
- 240000008790 Musa x paradisiaca Species 0.000 claims description 2
- 108090000526 Papain Proteins 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 2
- 235000015266 Plantago major Nutrition 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 241000192135 Prochloraceae Species 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- 108090000631 Trypsin Proteins 0.000 claims description 2
- 102000004142 Trypsin Human genes 0.000 claims description 2
- 235000009108 Urtica dioica Nutrition 0.000 claims description 2
- 244000274883 Urtica dioica Species 0.000 claims description 2
- 241000607598 Vibrio Species 0.000 claims description 2
- 241000607618 Vibrio harveyi Species 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 235000021028 berry Nutrition 0.000 claims description 2
- 229910052796 boron Inorganic materials 0.000 claims description 2
- 235000019835 bromelain Nutrition 0.000 claims description 2
- 150000003842 bromide salts Chemical class 0.000 claims description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 2
- 150000003841 chloride salts Chemical class 0.000 claims description 2
- 229960002376 chymotrypsin Drugs 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 230000037336 dry skin Effects 0.000 claims description 2
- 201000005884 exanthem Diseases 0.000 claims description 2
- 150000004673 fluoride salts Chemical class 0.000 claims description 2
- 150000004694 iodide salts Chemical class 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 235000019834 papain Nutrition 0.000 claims description 2
- 229940055729 papain Drugs 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 235000019419 proteases Nutrition 0.000 claims description 2
- 206010037844 rash Diseases 0.000 claims description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 2
- 229960004555 rutoside Drugs 0.000 claims description 2
- 235000002020 sage Nutrition 0.000 claims description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 2
- 229940098465 tincture Drugs 0.000 claims description 2
- 239000012588 trypsin Substances 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 241000207155 Heliobacterium Species 0.000 claims 1
- 241000589540 Pseudomonas fluorescens Species 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000002165 photosensitisation Effects 0.000 claims 1
- 239000012266 salt solution Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 36
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 7
- 229950003776 protoporphyrin Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 238000010672 photosynthesis Methods 0.000 description 4
- 230000029553 photosynthesis Effects 0.000 description 4
- 229930002868 chlorophyll a Natural products 0.000 description 3
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011946 reduction process Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000010627 oxidative phosphorylation Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000006552 photochemical reaction Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/748—Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/42—Colour properties
- A61K2800/43—Pigments; Dyes
- A61K2800/434—Luminescent, Fluorescent; Optical brighteners; Photosensitizers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
Definitions
- composition for the treatment of the skin surface Composition for the treatment of the skin surface
- the present invention relates to a composition for treating the skin surface and the use of this composition for the treatment of changes in the skin.
- the surface of the skin is not completely smooth, but locally furrowed with furrows, wrinkles and wrinkles.
- the skin relief is particularly characteristic on the fingers, palms and soles of the feet.
- the skin is regarded primarily as protection of the body, which in itself has various mechanisms for its own protection and can also activate accordingly.
- skin changes often occur due to diseases such as scars, warts, acne, dandruff, lichen, psoriasis, eczema and other skin conditions. Often these are due to environmental influences.
- the sufferers not only suffer physically, z. As itching, but also psychologically by the excruciating itching and scratching the skin with sometimes severe bleeding.
- the above-mentioned agents are synthetic products of the pharmaceutical industry. It is known that they cause significant side effects. Often it is the case that the skin no longer reacts to frequent use of these agents, since, for example, fungi / bacteria are known to be resistant to such substances.
- the present invention therefore relates to a skin surface treatment composition
- a skin surface treatment composition comprising a mixture of photosynthetic microorganisms and luminescent bacteria. It is preferred if the composition contains a chitin-based polysaccharide in aqueous solution.
- the subclaims further relate to the use of this composition for the treatment of changes in the skin.
- the invention further relates to the use of this composition for the treatment of changes in the skin.
- the composition contains two groups of microorganisms.
- the interplay between the photosynthetic microorganisms and the luminescent bacteria leads to photosynthetic microorganisms being stimulated by the luminescent bacteria to photosynthesize.
- the microorganisms operate photosynthesis with hydrogen sulfide and water as adduct and release sulfur or oxygen. They can also bind nitrogen as well as phosphate and degrade organic and inorganic matter.
- photosynthetic microorganisms are used, which are optionally phototrophic.
- Phototrophic optional means that the microorganisms can grow in the dark under both anaerobic conditions in the light and under aerobic conditions.
- the photosynthetic bacteria include gram-negative aerobic, rod-shaped and circular bacteria as well as gram-positive circular bacteria. these can
- composition according to the invention for treating the skin surface preferably contains in the mixture as optionally photoprobe microorganisms prochlorophytes, cyanobacteria, green sulfur bacteria, purple bacteria, chloroflexus-like forms and heliobacteria or Heliobacillus-like forms and mixtures of two or more thereof.
- all six mentioned microorganisms are present as a mixture.
- the light that drives photosynthesis is from the luminescent bacteria contained as a second essential component in the microorganism composition of the present invention.
- These luminescent bacteria have a luminosity, that is, they are able to emit light quanta. It is a system that is enzymatic; as an example the luciferin-luciferase system can be mentioned.
- photobacterium phosphoreum, Vibrio fischeri, Vibrio harveyi, Pseudomonas lucifera or Beneckea or mixtures of at least two are contained in the mixture according to the invention as luminescent bacteria.
- a third essential component of the skin surface treatment composition of the present invention is the chitin-based polysaccharide.
- Chitosan is preferably used as the chitin-based polysaccharide. This is the weakly basic, deacetylated and partially depolymerized crystalline chitosan, which has quite good dissolution properties.
- herbal extracts may furthermore be present.
- any mixture of herbs can be used here, as long as the effect of the composition according to the invention is not impaired.
- a herbal extract of plantain, hawthorn, sage, nettle, wild berry, birch or mint is particularly supportive.
- mixtures of the said herbs can be used, in which case at least two are present.
- composition according to the invention may contain as further active component an enzyme or an enzyme mixture. It has been found that preferably those enzymes or enzyme mixtures are suitable which originate from pineapple comosus, Carica papaya and / or pancreas. As examples may be mentioned papain, protease, trypsin, chymotrypsin, bromelain or rutoside. In particular, a mixture containing at least two of said enzymes is added.
- Be contained in the composition include, preferably, sodium, manganese, copper, boron, zinc, iron, sulfur, magnesium, potassium, calcium, phosphate or mixtures thereof.
- salts are preferably additionally incorporated. These are, for example, salts of alkali metals, alkaline earth metals and other metals.
- the anions used are preferably the chlorides, bromides, carbonates, bicarbonates, sulfates, hydrogen phosphates, fluorides and / or iodides of these metals.
- alkaline earth metals alkali metals and other metals, in cationic form, for example, calcium, magnesium, sodium, calcium, iron, ammonium, strontium and manganese.
- composition of the invention may also contain silica.
- the photosynthetic microorganisms and the luminescent bacteria in a ratio of 1: 10 to 1: 500, preferably 1: 100, contained in the inventive composition.
- the concentration of the bacteria, based on the composition preferably in a range of 2-3%.
- the ratio of the amount of microorganisms to chitin-based polysaccharide ranges from about 70:30 to 95: 5. A range of 90:10 is preferred here.
- alginates such as alginates, which are used for 02 production.
- other microorganisms may also be present which exert a positive effect on the composition according to the invention.
- lactic acid bacteria are used.
- the solution containing the components of the composition of the invention is an aqueous solution, that is, an aqueous, physiological solution.
- the treatment of the affected skin areas can be carried out particularly effectively if the composition contains microorganisms which release photosensitizers, which can then be incorporated into the diseased cells. Upon exposure to light, these photosensitizers are then activated to produce singlet oxygen or other reactive radicals which, through oxidation and reduction processes, ablate the cells of the affected skin area. In principle, it is also possible to add the photosensitizers directly to the composition.
- the invention according to the composition is absolutely a biological product that can be applied to the skin with good success, without the risk of side effects. It works effectively in the treatment of changes in the skin.
- the changes in the skin are usually due to the fact that the skin is damaged by environmental influences. This includes the fungal and bacterial attack of the skin. It is known that, for example in athlete's foot, the skin itches to itch and shed the top layers of the skin like scales.
- composition according to the invention can also be any indifferent general skin itching effectively with the present be treated composition according to the invention.
- the composition of the invention has also been successful in the treatment of rashes. So even extremely dry skin with possibly dandruff can be successfully treated.
- application of the composition according to the invention in eczema, especially in the arm and squat, has brought rapid and long-lasting relief.
- composition according to the invention can be applied in any dosage form which is suitable for application to the skin. Examples include tincture, ointment, cream and lotion.
- the composition of the invention may also be present in bath or shower additives. It goes without saying that the composition according to the invention is processed with the customary additives for the mentioned dosage forms.
- composition according to the invention can be prepared, for example, as follows.
- Suitable microorganisms for producing photosensitizers are, for example, bacteriochlorophyll, Monascus purpurus (Pigment 3658), Limicola-Nadson (cell dye 2145) or Pseudomonas fluorescene.
- bacteriochlorophyll results in a chlorophyll A reaction, upon irradiation with light bacterial release of aminolevulinic acid, forming protoporphyrin IX (PPIX), which is selectively taken up and stored by the affected cells.
- PPIX protoporphyrin IX
- This PPIX is then activated by exposure to light, and as a result of the photodynamic effects of electron transfer, the above-described formation of singlet oxygen and radicals within the cell occurs, which are then broken up and damaged by oxidation and reduction processes.
- the destruction of the cells can then be done in two ways, done by necrosis or apoptosis.
- the principal efficiency of the photodynamic process can be defined by the following steps:
- composition of the invention may also be present as a set.
- a container may contain the microorganisms, herbal extracts and chitin-based polysaccharide.
- the salt and the enzyme or the enzyme mixture are filled. The user can then use a suitable instructions for its composition for Make the skin surface yourself and apply immediately to the affected skin.
- a skin surface treating composition comprising a mixture of photosynthetic microorganisms and luminescent bacteria and a chitin-based polysaccharide in aqueous solution.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Beschreibung description
Zusammensetzung zur Behandlung der Hautoberf1 ächeComposition for the treatment of the skin surface
Die vorliegende Erfindung betrifft eine Zusammensetzung zur Behandlung der Hautoberfläche und die Verwendung dieser Zusammensetzung zur Behandlung von Veränderungen der Haut .The present invention relates to a composition for treating the skin surface and the use of this composition for the treatment of changes in the skin.
Die Oberfläche der Haut (Epidermis) ist nicht durchgehend glatt, sondern lokal gefurcht mit Furchungen, Falten und Runzeln. Das Hautrelief ist besonders charakteristisch an den Fingern, Handflächen und Fußsohlen.The surface of the skin (epidermis) is not completely smooth, but locally furrowed with furrows, wrinkles and wrinkles. The skin relief is particularly characteristic on the fingers, palms and soles of the feet.
Man betrachtet die Haut vornehmlich als Schutz des Körpers, die an sich verschiedene Mechanismen zu ihrem eigenen Schutz birgt und auch entsprechend aktivieren kann. Dennoch kommt es oftmals zu Veränderungen der Haut durch Erkrankungen, wie Narben, Warzen, Akne, Schuppen, Flechten, Psoriasis, Ekzeme, sowie andere Hautleiden. Oftmals sind diese auf Umwelteinflüsse zurückzuführen. Die Betroffenen leiden nicht nur physisch, z. B. an Juckreiz, sondern auch psychisch durch den quälenden Juckreiz und das Aufkratzen der Haut mit zum Teil starken Blutungen.The skin is regarded primarily as protection of the body, which in itself has various mechanisms for its own protection and can also activate accordingly. However, skin changes often occur due to diseases such as scars, warts, acne, dandruff, lichen, psoriasis, eczema and other skin conditions. Often these are due to environmental influences. The sufferers not only suffer physically, z. As itching, but also psychologically by the excruciating itching and scratching the skin with sometimes severe bleeding.
So treten auch häufig bakterielle Infektionen auf der Hautoberfläche auf, die neben dem Befall mit Pilzen und Hefen äußerst unangenehm sind. Es kommt hierbei zu einem starken Juckreiz und damit zu einem schmerzhaften Aufkratzen der Haut.Thus, bacterial infections often occur on the skin surface, in addition to the infestation are extremely unpleasant with mushrooms and yeasts. It comes here to a strong itching and thus to a painful scratching of the skin.
Es gibt bereits zur Bekämpfung von Pilz- undThere are already to combat fungal and
Bakterieninfektionen Antimykotika und Antibiotika. Des weiteren werden bei indifferenten Juckerscheinungen sogenannte Antipruriginosa verabreicht.Bacterial infections antifungals and antibiotics. Furthermore, so-called antipruriticosa are administered in indifferent itching symptoms.
Bei den vorstehend genannten Mitteln handelt es sich um synthetische Produkte der pharmazeutischen Industrie. Es ist bekannt, dass sie erhebliche Nebenwirkungen hervorrufen. Oftmals ist es so, dass die Haut bei häufigem Gebrauch dieser Mittel nicht mehr darauf reagiert, da beispielsweise Pilze/Bakterien bekanntermaßen resistent gegen solche Stoffe werden.The above-mentioned agents are synthetic products of the pharmaceutical industry. It is known that they cause significant side effects. Often it is the case that the skin no longer reacts to frequent use of these agents, since, for example, fungi / bacteria are known to be resistant to such substances.
Es bestand daher ein Bedarf dahingehend, ein Mittel bzw. eine Zusammensetzung zur Verfügung zu stellen, mit der die Hautoberflache behandelt werden kann, ohne dass die Gefahr von Nebenwirkungen durch die Behandlung mit diesen Mitteln auftritt. Es bestand weiter der Wunsch, eine Alternative zu den etablierten pharmazeutischen Präparaten bieten zu können und auf ein natürliches Präparat zurückgreifen zu können, das ohne Bedenken auf der Haut angewendet werden kann.There was therefore a need to provide an agent or composition with which the skin surface can be treated without the risk of side effects from the treatment with these agents. There was also a desire to be able to offer an alternative to the established pharmaceutical preparations and to be able to resort to a natural preparation, which can be applied without hesitation to the skin.
Diese Aufgabe wird mit einer Zusammensetzung gemäß Patentanspruch 1 gelöst .This object is achieved with a composition according to claim 1.
Die vorliegende Erfindung betrifft daher eine Zusammensetzung zur Behandlung der Hautoberfläche, die eine Mischung aus photosynthetisch arbeitenden Mikroorganismen und Leuchtbakterien. Dabei wird es bevorzugt, wenn die Zusammensetzung ein Polysaccharid auf Chitinbasis in wassriger Lösung enthält. Die Unteransprüche betreffen weiterhin die Verwendung dieser Zusammensetzung zur Behandlung von Veränderungen der Haut .The present invention therefore relates to a skin surface treatment composition comprising a mixture of photosynthetic microorganisms and luminescent bacteria. It is preferred if the composition contains a chitin-based polysaccharide in aqueous solution. The subclaims further relate to the use of this composition for the treatment of changes in the skin.
Die Erfindung betrifft weiterhin die Verwendung dieser Zusammensetzung zur Behandlung von Veränderungen der Haut.The invention further relates to the use of this composition for the treatment of changes in the skin.
Es ist erfindungswesentlich, dass die Zusammensetzung zwei Gruppen von Mikroorganismen enthält. Das Wechselspiel zwischen den photosynthetisch arbeitenden Mikroorganismen und den Leuchtbakterien führt dazu, dass die photosynthetisch arbeitenden Mikroorganismen durch die Leuchtbakterien zur Photosynthese angeregt werden. Die Mikroorganismen betreiben die Photosynthese mit Schwefelwasserstoff und Wasser als Addukt und setzen Schwefel bzw. Sauerstoff frei. Ferner können sie Stickstoff sowie Phosphat binden und organische und anorganische Materie abbauen.It is essential to the invention that the composition contains two groups of microorganisms. The interplay between the photosynthetic microorganisms and the luminescent bacteria leads to photosynthetic microorganisms being stimulated by the luminescent bacteria to photosynthesize. The microorganisms operate photosynthesis with hydrogen sulfide and water as adduct and release sulfur or oxygen. They can also bind nitrogen as well as phosphate and degrade organic and inorganic matter.
Bevorzugt werden in der erfindungsgemäßen Zusammensetzung photosynthetisch arbeitende Mikroorganismen verwendet, die fakultativ phototroph sind. Phototroph fakultativ bedeutet, dass die Mikroorganismen sowohl unter anaeroben Bedingungen im Licht als auch unter aeroben Bedingungen im Dunklen wachsen können.Preferably in the composition according to the invention photosynthetic microorganisms are used, which are optionally phototrophic. Phototrophic optional means that the microorganisms can grow in the dark under both anaerobic conditions in the light and under aerobic conditions.
Zu den Photosynthesebakterien gehören grammnegative aerobe, stabförmige und kreisförmige Bakterien sowie grammpositive kreisförmige Bakterien. Diese könnenThe photosynthetic bacteria include gram-negative aerobic, rod-shaped and circular bacteria as well as gram-positive circular bacteria. these can
Endosporen aufweisen oder ohne Sporen vorhanden sein.Have endospores or be present without spores.
Dazu zählen beispielsweise auch grammpositiveThese include, for example, grammpositive
Aktinomyceten und verwandte Bakterien. Die erfindungsgemäße Zusammensetzung zur Behandlung der Hautoberfläche enthält bevorzugt in der Mischung als fakultativ photoprobe Mikroorganismen Prochlorophyten, Cyanobakterien, grüne Schwefelbakterien, Purpurbakterien, Chlorflexus-ähnliche Formen und Heliobakterien oder Heliobacillus-ähnliche Formen sowie Mischungen aus zwei oder mehr daraus . In einer ganz besonderen Ausführungsform liegen alle sechs genannten Mikroorganismen als Mischung vor.Actinomycetes and related bacteria. The composition according to the invention for treating the skin surface preferably contains in the mixture as optionally photoprobe microorganisms prochlorophytes, cyanobacteria, green sulfur bacteria, purple bacteria, chloroflexus-like forms and heliobacteria or Heliobacillus-like forms and mixtures of two or more thereof. In a very special embodiment, all six mentioned microorganisms are present as a mixture.
Das Licht, das die Photosynthese antreibt, stammt von den Leuchtbakterien, die als zweite essentielle Komponente in der Mikroorganismenzusammensetzung der vorliegenden Erfindung enthalten sind. Diese Leuchtbakterien besitzen eine Leuchtkraft, das heißt, sie sind in der Lage, Lichtquanten auszusenden. Es handelt sich hierbei um ein System, das enzymatisch abläuft; als Beispiel kann das Luciferin-Luciferase-System genannt werden.The light that drives photosynthesis is from the luminescent bacteria contained as a second essential component in the microorganism composition of the present invention. These luminescent bacteria have a luminosity, that is, they are able to emit light quanta. It is a system that is enzymatic; as an example the luciferin-luciferase system can be mentioned.
In einer bevorzugten Ausführungsform sind in der erfin- dungsgmäßen Mischung als Leuchtbakterien Photobacterium phosphoreum, Vibrio fischeri, Vibrio harveyi, Pseudomonas lucifera oder Beneckea oder Mischungen aus mindestens zwei enthalten.In a preferred embodiment, photobacterium phosphoreum, Vibrio fischeri, Vibrio harveyi, Pseudomonas lucifera or Beneckea or mixtures of at least two are contained in the mixture according to the invention as luminescent bacteria.
Eine dritte wesentliche Komponente der erfindungsgemäßen Zusammensetzung zur Behandlung der Hautoberfläche ist das Polysaccharid auf Chitinbasis. Bevorzugt wird als Polysaccharid auf Chitinbasis das Chitosan verwendet. Es handelt sich hierbei um das schwachbasische, desacetylierte und teilweise depolymerisierte kristalline Chitosan, das recht gute Lösungseigenschaften aufweist.A third essential component of the skin surface treatment composition of the present invention is the chitin-based polysaccharide. Chitosan is preferably used as the chitin-based polysaccharide. This is the weakly basic, deacetylated and partially depolymerized crystalline chitosan, which has quite good dissolution properties.
Es hat sich erfindungsgemäß herausgestellt, dass gerade die Kombination der Mischung aus den photosynthetisch arbeitenden Mikroorganismen und Leuchtbakterien mit dem Polysacharid auf Chitinbasis, bevorzugt Chitosan, eine erkrankte Hautoberfläche effektiv behandeln kann. Es handelt sich hierbei um rein natürliche Stoffe, die von der Haut hervorragend akzeptiert werden und keine Nebenwirkungen zeigen.It has been found according to the invention that it is precisely the combination of the mixture of the photosynthetic microorganisms and luminescent bacteria with the Chitin-based polysaccharide, preferably chitosan, can effectively treat a diseased skin surface. These are purely natural substances that are excellently accepted by the skin and show no side effects.
Zur Optimierung der erfindungsgemäßen Zusammensetzung können weiterhin Kräuterauszüge enthalten sein. Im Prinzip kann jede Mischung aus Kräutern hier verwendet werden, so lange die Wirkung der erfindungsgemäßen Zusammensetzung nicht beeinträchtigt wird. Es hat sich allerdings herausgestellt, dass ein Kräuterauszug aus Spitzwegerich, Weißdorn, Salbei, Brennnessel, Waldbeeren, Birke oder Minze besonders unterstützend wird. Selbstverständlich können auch Mischungen aus den genannten Kräutern verwendet werden, wobei dann mindestens zwei vorhanden sind.In order to optimize the composition according to the invention, herbal extracts may furthermore be present. In principle, any mixture of herbs can be used here, as long as the effect of the composition according to the invention is not impaired. However, it has turned out that a herbal extract of plantain, hawthorn, sage, nettle, wild berry, birch or mint is particularly supportive. Of course, mixtures of the said herbs can be used, in which case at least two are present.
Die erfindungsgemäße Zusammensetzung kann als weitere wirksame Komponente ein Enzym oder eine Enzymmischung enthalten. Es hat sich herausgestellt, dass bevorzugt solche Enzyme bzw. Enzymmischungen geeignet sind, die aus Ananas comosus, Carica papaya und/oder Pankreas stammen. Als Beispiele können hierzu Papain, Protease, Trypsin, Chymotrypsin, Bromelain oder Rutosid genannt werden. Insbesondere wird eine Mischung hunzugegeben, die mindestens zwei der genannten Enzyme enthält .The composition according to the invention may contain as further active component an enzyme or an enzyme mixture. It has been found that preferably those enzymes or enzyme mixtures are suitable which originate from pineapple comosus, Carica papaya and / or pancreas. As examples may be mentioned papain, protease, trypsin, chymotrypsin, bromelain or rutoside. In particular, a mixture containing at least two of said enzymes is added.
Zur Stabilisierung insbesondere der mikrobiologischen Mischung können Spurenelemente in der erfindungsgemäßenTo stabilize in particular the microbiological mixture trace elements in the inventive
Zusammensetzung enthalten sein. Dazu zählen bevorzugt, Natrium, Mangan, Kupfer, Bor, Zink, Eisen, Schwefel, Magnesium, Kalium, Calcium, Phosphat oder Mischungen daraus . Für eine weitere Stabilisierung der gesamten Zusammensetzung werden bevorzugt zusätzlich noch Salze eingearbeitet. Es handelt sich hierbei beispielsweise um Salze von Alkalimetallen, Erdalkalimetallen und anderen Metallen. Als Anionen werden bevorzugt die Chloride, Bromide, Carbonate, Hydrogencarbonate, Sulfate, Hydrogenphosphate, Fluoride und/oder Jodide dieser Metalle verwendet.Be contained in the composition. These include, preferably, sodium, manganese, copper, boron, zinc, iron, sulfur, magnesium, potassium, calcium, phosphate or mixtures thereof. For a further stabilization of the entire composition, salts are preferably additionally incorporated. These are, for example, salts of alkali metals, alkaline earth metals and other metals. The anions used are preferably the chlorides, bromides, carbonates, bicarbonates, sulfates, hydrogen phosphates, fluorides and / or iodides of these metals.
Als Beispiele für die Erdalkalimetalle, Alkalimetalle und die anderen Metalle können, in kationischer Form, beispielsweise Calcium, Magnesium, Natrium, Calcium, Eisen, Ammonium, Strontium und Mangan.As examples of the alkaline earth metals, alkali metals and other metals, in cationic form, for example, calcium, magnesium, sodium, calcium, iron, ammonium, strontium and manganese.
Nach Bedarf kann die erfindungsgemäße Zusammensetzung auch Kieselsäure enthalten.If necessary, the composition of the invention may also contain silica.
In einer bevorzugten Ausführungsform sind die photosynthetisch arbeitenden Mikroorganismen und die Leuchtbakterien in einem Verhältnis von 1 : 10 bis 1 : 500, vorzugsweise 1 : 100, in der erfindungsgemaßen Zusammensetzung enthalten. Die Konzentration der Bakterien liegt, bezogen auf die Zusammensetzung, bevorzugt in einem Bereich von 2 - 3 % .In a preferred embodiment, the photosynthetic microorganisms and the luminescent bacteria in a ratio of 1: 10 to 1: 500, preferably 1: 100, contained in the inventive composition. The concentration of the bacteria, based on the composition, preferably in a range of 2-3%.
Es hat sich herausgestellt, dass das Verhältnis der Menge von Mikroorganismen zu Polysaccharid auf Chitinbasis in einem Bereich von etwa 70 : 30 bis 95 : 5 liegt. Ein Bereich von 90 : 10 ist hier bevorzugt.It has been found that the ratio of the amount of microorganisms to chitin-based polysaccharide ranges from about 70:30 to 95: 5. A range of 90:10 is preferred here.
Des weiteren können auch noch andere unterstützende Komponenten in der vorliegenden biologischen Zusammensetzung enthalten sein. Dazu gehören beispielsweise Alginderivate, wie Alginate, die zur 02- Produktion dienen. Des weiteren können auch noch andere Mikroorganismen enthalten sein, die eine positive Wirkung auf die erfindungsgemäße Zusammensetzung ausüben. Bevorzugt werden Milchsäurebakterien eingesetzt.Furthermore, other supporting components may also be included in the present biological composition. These include, for example, alginates, such as alginates, which are used for 02 production. Furthermore, other microorganisms may also be present which exert a positive effect on the composition according to the invention. Preferably, lactic acid bacteria are used.
Die Lösung, in der die Bestandteile der erfindungsgemäßen Zusammensetzung enthalten sind, ist eine wässrige Lösung, das heißt, eine wässrige, physiologische Lösung.The solution containing the components of the composition of the invention is an aqueous solution, that is, an aqueous, physiological solution.
Die Behandlung der befallenen Hautbereiche läßt sich besonders effektiv durchführen, wenn die Zusammensetzung Mikroorganismen enthält, die Photosensibilisatoren freisetzen, die dann in die erkrankten Zellen eingelagert werden können. Durch Lichteinwirkung werden diese Photosensibilisatoren dann aktiviert und produzieren Singulett-Sauerstoff oder sonstige reaktive Radikale, die durch Oxidations- und Reduktionsvorgänge die Zellen der befallenen Hautbereich ab. Prinzipiell ist es auch möglich, die Photosensibilisatoren der Zusammensetzung direkt beizugeben.The treatment of the affected skin areas can be carried out particularly effectively if the composition contains microorganisms which release photosensitizers, which can then be incorporated into the diseased cells. Upon exposure to light, these photosensitizers are then activated to produce singlet oxygen or other reactive radicals which, through oxidation and reduction processes, ablate the cells of the affected skin area. In principle, it is also possible to add the photosensitizers directly to the composition.
Die Erfindung gemäß der Zusammensetzung ist absolut ein biologisches Produkt, das mit gutem Erfolg, ohne Gefahr von Nebenwirkungen, auf die Haut aufgetragen werden kann. Es wirkt effektiv bei der Behandlung von Veränderungen der Haut .The invention according to the composition is absolutely a biological product that can be applied to the skin with good success, without the risk of side effects. It works effectively in the treatment of changes in the skin.
Die Veränderungen der Haut sind meist darauf zurückzuführen, dass die Haut durch Umwelteinflüsse geschädigt wird. Dazu zählt der Pilz- und Bakterienbefall der Haut. Es ist bekannt, dass, beispielsweise bei Fußpilz, die Haut anfängt zu jucken und sich die obersten Schichten der Haut schuppenartig ablösen.The changes in the skin are usually due to the fact that the skin is damaged by environmental influences. This includes the fungal and bacterial attack of the skin. It is known that, for example in athlete's foot, the skin itches to itch and shed the top layers of the skin like scales.
Es kann aber auch jedes indifferente allgemeine Hautjucken effektiv mit der vorliegenden erfindungsgemäßen Zusammensetzung behandelt werden. Die erfindungsgemäße Zusammensetzung hat sich ebenfalls erfolgreich bei der Behandlung von Ausschlägen erwiesen. So kann auch extrem trockene Haut mit gegebenenfalls Schuppenbefall erfolgreich behandelt werden. So hat auch ein Auftragen der erfindungsgemäßen Zusammensetzung bei Neurodermitis, insbesondere in den Arm- und Kniebeugen, rasche und lang andauernde Linderung gebracht .But it can also be any indifferent general skin itching effectively with the present be treated composition according to the invention. The composition of the invention has also been successful in the treatment of rashes. So even extremely dry skin with possibly dandruff can be successfully treated. Thus, application of the composition according to the invention in eczema, especially in the arm and squat, has brought rapid and long-lasting relief.
Die erfindungsgemäße Zusammensetzung kann in jeder Darei- chungsform appliziert werden, die geeignet ist, auf die Haut aufgetragen zu werden. Als Beispiele können hier die Tinktur, Salbe, Creme und Lotion genannt werden. Die erfindungsgemäße Zusammensetzung kann ebenfalls in Bade- bzw. Duschzusätzen vorliegen. Es ist selbstverständlich, dass die erfindungsgemäße Zusammensetzung mit den üblichen Zusatzstoffen für die genannten Dareichungsformen verarbeitet wird.The composition according to the invention can be applied in any dosage form which is suitable for application to the skin. Examples include tincture, ointment, cream and lotion. The composition of the invention may also be present in bath or shower additives. It goes without saying that the composition according to the invention is processed with the customary additives for the mentioned dosage forms.
Die erfindungsgemäße Zusammensetzung kann beispielsweise wie folgt hergestellt werden.The composition according to the invention can be prepared, for example, as follows.
1. Es werden 400 ml der Mischung aus photosynthetisch arbeitenden Mikroorganismen und Leuchtbakterien sowie einen Anteil an Photosensibilisatoren freisetzenden Mikroorganismen, beispielsweise das Bakteriochlorophyll und das Polysaccharid auf Chitinbasis mit 100 ml Kräuterauszug vermischt. Die Mischung wird dann für 5 - 10 Minuten im Ultraschallbad bewegt. 2. Es werden 125 bis 250 ml der obigen Mischung in 5 - 7 1 Wasser bei 37 % eingerührt.1. 400 ml of the mixture of photosynthetic microorganisms and luminescent bacteria and a proportion of photosensitizer-releasing microorganisms, for example the bacteriochlorophyll and the chitin-based polysaccharide, are mixed with 100 ml of herbal extract. The mixture is then agitated for 5-10 minutes in an ultrasonic bath. 2. Stir 125 to 250 ml of the above mixture in 5-7 liters of water at 37%.
3. Anschließend werden 50 bis 100 g Salz hinzugegeben und gerührt .3. Subsequently, 50 to 100 g of salt are added and stirred.
4. Als letztes werden 1 - 2 g Enzyme untergemischt. Durch die Zugabe von Photosensibilisatoren freisetzenden Mikroorganismen kann die Wirkung der Zusammensetzung durch einen photodynamischen Prozess unterstützt werden. Dabei werden vorzugsweise Mirkoorganismen verwendet, die bei Anregung mit Licht Photosensibilisatoren freisetzen. Bei Aktivierung dieser Photosensibilisatoren mittels Licht wird infolge der ablaufenden photochemischen Reaktionen sowie Energieübertragungsprozessen Singulett- Sauerstoff und sonstige reaktive Substanzen, wie beispielsweise Radikale als angeregter Zustand des Photosensibilisators gebildet. Diese in den befallenen Zellen freigesetzten reaktiven Substanzen bauen durch Oxidations- und ReduktionsVorgänge diese Zellen ab. Als geeignete Mikroorganismen zur Erzeugung von Photosensibilisatoren kommen beispielsweise das Bakteriochlorophyll, das Monascus Purpurus (Pigment 3658) , das Limicola-Nadson (Zellfarbstoff 2145) oder das Pseudomonasluoreszens in Frage.4. Finally, 1 - 2 g of enzymes are mixed in. By adding photosensitizer-releasing microorganisms, the effect of the composition can be assisted by a photodynamic process. In this case, microorganisms are preferably used which release photosensitizers on excitation with light. Upon activation of these photosensitizers by means of light, singlet oxygen and other reactive substances, such as, for example, radicals as the excited state of the photosensitizer, are formed as a result of the ongoing photochemical reactions and energy transfer processes. These reactive substances released in the affected cells degrade these cells by oxidation and reduction processes. Suitable microorganisms for producing photosensitizers are, for example, bacteriochlorophyll, Monascus purpurus (Pigment 3658), Limicola-Nadson (cell dye 2145) or Pseudomonas fluorescene.
Bei der Verwendung eines Bakteriochlorophylls kommt es dann zu einer Chlorophyll-A-Reaktion, bei Bestrahlung mit Licht erfolgt die bakterielle Freisetzung von Aminolävulinsäure, wodurch Protoporphyrin IX (PPIX) , gebildet wird das selektiv von den befallenen Zellen aufgenommen und gespeichert wird. Dieses PPIX wird dann durch Lichteinwirkung aktiviert und infolge der photodynamischen Effekte durch Elektronentransfer kommt es dann zur vorstehend beschriebenen Bildung von Singulett-Sauerstoff und Radikalen innerhalb der Zelle, die dann durch Oxidation- und Reduktionsvorgänge aufgebrochen und beschädigt werden. Die Zerstörung der Zellen können dann auf zwei Arten geschehen, durch Nekrose oder Apoptose geschehen. Der prinzipielle Wirkungsgrad des photodynamischen Prozesses läßt sich durch die folgenden Schritte definieren:The use of a bacteriochlorophyll then results in a chlorophyll A reaction, upon irradiation with light bacterial release of aminolevulinic acid, forming protoporphyrin IX (PPIX), which is selectively taken up and stored by the affected cells. This PPIX is then activated by exposure to light, and as a result of the photodynamic effects of electron transfer, the above-described formation of singlet oxygen and radicals within the cell occurs, which are then broken up and damaged by oxidation and reduction processes. The destruction of the cells can then be done in two ways, done by necrosis or apoptosis. The principal efficiency of the photodynamic process can be defined by the following steps:
1. Fixierung von Stickstoff1. fixation of nitrogen
2. Chemolithotropie2. Chemolithotropy
3. Alkanoxidation3. alkane oxidation
4. Bakterielle Biolumineszenz4. Bacterial bioluminescence
5. Oxidative Phosphorylierung 6. Protoporphyrin IX (PPIX) Fluoreszenz5. Oxidative Phosphorylation 6. Protoporphyrin IX (PPIX) Fluorescence
7. Bakterielle und pflanzliche Chlorophyll-A Fluoreszenz7. Bacterial and plant chlorophyll A fluorescence
8. Photosynthese der Cyanobakterie und Purpurbakterie8. Photosynthesis of cyanobacteria and purple bacteria
9. Photosynthese durch Archaea 10. Antibiotische Reaktion durch Milchsäure-Bakterie9. Photosynthesis by Archaea 10. Antibiotic reaction by lactic acid bacteria
Mit Hilfe der Chlorophyll-A Fluoreszenz wird das Medium lichtempfindlich gemacht. Biopolymere, Farbpigmente abgebende Mikroorganismen und Biokatalysatoren werden teilweise zum lichtempfindlichen PPIX umgewandelt. Durch die oxidative Phosphorylierung (blaues Licht) wird PPIX wie eine kleine Batterie aufgeladen und kann so einen Teil der Energie auf gewöhnlichen Sauerstoff übertragen. Dabei wird umweltfreundlicher reaktionsfreudiger Singulett-Sauerstoff freigesetzt.With the help of chlorophyll-A fluorescence, the medium is made sensitive to light. Biopolymers, color pigments releasing microorganisms and biocatalysts are partially converted to photosensitive PPIX. By oxidative phosphorylation (blue light) PPIX is charged like a small battery and can transfer part of the energy to ordinary oxygen. This releases more environmentally friendly singlet oxygen.
Es ist möglich, dass der Anwender selbst frisch die erfindungsgemäße Zusammensetzung zubereiten kann. So kann die erfindungsgemäße Zusammensetzung auch als Set vorliegen. In einem Behälter können die Mikroorganismen, die Kräuterauszüge sowie das Polysaccharid auf Chitinbasis enthalten sein. In zwei weiteren Behältern sind das Salz sowie das Enzym bzw. die Enzymmischung eingefüllt. Der Anwender kann dann anhand einer geeigneten Gebrauchsanweisung seine Zusammensetzung zur Behandlung der Hautoberflache selbst herstellen und sofort auf die betroffenen Hautstellen applizieren.It is possible that the user himself may freshly prepare the composition according to the invention. Thus, the composition of the invention may also be present as a set. A container may contain the microorganisms, herbal extracts and chitin-based polysaccharide. In two other containers, the salt and the enzyme or the enzyme mixture are filled. The user can then use a suitable instructions for its composition for Make the skin surface yourself and apply immediately to the affected skin.
Ein Rückgang der Beschwerden, wie beispielsweise der Juckreiz, sowie eine deutliche Besserung der Struktur der Hautoberfläche, wie der Weggang von Schuppen und Rötungen, sind bereits schon nach kurzer Zeit zu beobachten, meistens schon nach wenigen Tagen.A decrease in the symptoms, such as the itching, as well as a significant improvement in the structure of the skin surface, such as the departure of dandruff and redness, are already observed after a short time, usually after a few days.
Es wird eine Zusammensetzung zur Behandlung der Hautoberfläche beschrieben, die eine Mischung aus photosynthetisch arbeitenden Mikroorganismen und Leuchtbakterien sowie ein Polysaccharid auf Chitinbasis in wassriger Lösung enthält. There is described a skin surface treating composition comprising a mixture of photosynthetic microorganisms and luminescent bacteria and a chitin-based polysaccharide in aqueous solution.
Claims
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002365621A AU2002365621A1 (en) | 2001-11-29 | 2002-11-28 | Composition for treating the surface of the skin |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10158712A DE10158712A1 (en) | 2001-11-29 | 2001-11-29 | Composition for the treatment of the skin surface |
| DE10158712.0 | 2001-11-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2003047533A2 true WO2003047533A2 (en) | 2003-06-12 |
| WO2003047533A3 WO2003047533A3 (en) | 2003-10-16 |
Family
ID=7707471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/DE2002/004372 WO2003047533A2 (en) | 2001-11-29 | 2002-11-28 | Composition for treating the surface of the skin |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2002365621A1 (en) |
| DE (1) | DE10158712A1 (en) |
| WO (1) | WO2003047533A2 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2924021A1 (en) * | 2007-11-27 | 2009-05-29 | Du Vernet Michele Eymard | Cosmetic and/or dermatological composition, useful to treat skin by skin cell rejuvenation using photodynamic therapy technique, psoriasis, acne, vitiligo and melasma, comprises chlorophyll as photo sensitizing substance |
| CN103641926A (en) * | 2013-12-05 | 2014-03-19 | 淮海工学院 | Extraction method of Chinese hawthorn leaf polysaccharide |
| WO2017184601A1 (en) * | 2016-04-19 | 2017-10-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of gram negative species to treat atopic dermatitis |
| US10293005B2 (en) | 2016-04-19 | 2019-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of gram negative species to treat atopic dermatitis |
| US10973841B2 (en) | 2018-05-11 | 2021-04-13 | Forte Subsidiary, Inc. | Compositions for the treatment of skin conditions |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004060246A1 (en) * | 2004-12-15 | 2006-07-06 | Cognis Ip Management Gmbh | Use of chitosan for itching |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6379702B1 (en) * | 2000-07-05 | 2002-04-30 | Hydromer, Inc. | Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives |
| KR100315381B1 (en) * | 2000-07-18 | 2001-11-26 | 김영준 | Chitosan microflake and method of manufacturing them |
-
2001
- 2001-11-29 DE DE10158712A patent/DE10158712A1/en not_active Withdrawn
-
2002
- 2002-11-28 AU AU2002365621A patent/AU2002365621A1/en not_active Abandoned
- 2002-11-28 WO PCT/DE2002/004372 patent/WO2003047533A2/en not_active Application Discontinuation
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2924021A1 (en) * | 2007-11-27 | 2009-05-29 | Du Vernet Michele Eymard | Cosmetic and/or dermatological composition, useful to treat skin by skin cell rejuvenation using photodynamic therapy technique, psoriasis, acne, vitiligo and melasma, comprises chlorophyll as photo sensitizing substance |
| WO2009095568A3 (en) * | 2007-11-27 | 2009-10-15 | Eymard Du Vernet Michele | Composition for photodynamic skin treatment |
| CN103641926A (en) * | 2013-12-05 | 2014-03-19 | 淮海工学院 | Extraction method of Chinese hawthorn leaf polysaccharide |
| US10293005B2 (en) | 2016-04-19 | 2019-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of gram negative species to treat atopic dermatitis |
| US10500238B2 (en) | 2016-04-19 | 2019-12-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of gram negative species to treat atopic dermatitis |
| US10195236B2 (en) | 2016-04-19 | 2019-02-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of gram negative species to treat atopic dermatitis |
| CN109310626A (en) * | 2016-04-19 | 2019-02-05 | 美利坚合众国,由健康及人类服务部部长代表 | Use of Gram-negative species in the treatment of atopic dermatitis |
| US10206957B2 (en) | 2016-04-19 | 2019-02-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of gram negative species to treat atopic dermatitis |
| WO2017184601A1 (en) * | 2016-04-19 | 2017-10-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of gram negative species to treat atopic dermatitis |
| JP2019513769A (en) * | 2016-04-19 | 2019-05-30 | ザ ユナイテッド ステイツ オブ アメリカ，アズ レプリゼンテッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Use of Gram-negative species to treat atopic dermatitis |
| KR20190003582A (en) * | 2016-04-19 | 2019-01-09 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Uses of Gram negative species to treat atopic dermatitis |
| US10653727B2 (en) | 2016-04-19 | 2020-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of gram negative species to treat atopic dermatitis |
| US10668114B2 (en) | 2016-04-19 | 2020-06-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of gram negative species to treat atopic dermatitis |
| US10682379B2 (en) | 2016-04-19 | 2020-06-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of gram negative species to treat atopic dermatitis |
| US10946049B2 (en) | 2016-04-19 | 2021-03-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of gram negative species to treat atopic dermatitis |
| US10946048B2 (en) | 2016-04-19 | 2021-03-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of gram negative species to treat atopic dermatitis |
| KR102340006B1 (en) | 2016-04-19 | 2021-12-20 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Use of Gram-negative species to treat atopic dermatitis |
| US10980846B2 (en) | 2016-04-19 | 2021-04-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of gram negative species to treat atopic dermatitis |
| US10973841B2 (en) | 2018-05-11 | 2021-04-13 | Forte Subsidiary, Inc. | Compositions for the treatment of skin conditions |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002365621A8 (en) | 2003-06-17 |
| DE10158712A1 (en) | 2003-06-26 |
| WO2003047533A3 (en) | 2003-10-16 |
| AU2002365621A1 (en) | 2003-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0217975B1 (en) | Salt mixture for the treatment of psoriasis and other skin diseases | |
| DE60124777T2 (en) | ANTIOXIDANT IN WATER MOLECULAR COLLECTIONS | |
| DE69328438T2 (en) | OAK Bark EXTRACT-RELATED SYNTHETIC PREPARATIONS AND METHOD FOR USE | |
| WO2003047533A2 (en) | Composition for treating the surface of the skin | |
| WO2012022659A9 (en) | Synergistic activity of modulators of the no metabolism and of nadph oxidase in the sensitization of tumour cells | |
| EP2358642B2 (en) | Clinoptilolite or clinoptilolite comprising mixtures | |
| EP0535317B1 (en) | Drug for the treatment of agitation state and nerve dysfonction | |
| EP0065246B1 (en) | Process for producing anabolic, respiration promoting, low-molecular-weight-active substances for prophylactic, therapeutic and cell and tissue culture technique purposes | |
| DE69613190T2 (en) | COMPOSITIONS WITH ANTIVIRAL EFFECTS AND METHOD FOR THE PRODUCTION | |
| DE102006037632A1 (en) | Microbiological mixture, useful for applying on a skin surface to treat e.g. fungus and bacteria infections, comprises piezoelectric nano-structures, reductive/oxidative microorganisms, conjugated biopolymer and/or 5-aminolevulinic acid | |
| DE2715893A1 (en) | METHOD FOR SELECTIVE INACTIVATION OF AMYLASE | |
| DE1922601A1 (en) | New enzyme inhibitors and their manufacture | |
| EP1687238B1 (en) | Reactive chlorine compounds, the derivatives, anions, and salts thereof, method for the production thereof, and use thereof | |
| DE3712505A1 (en) | Salt mixture for the treatment of psoriasis and other skin disorders | |
| KR20120067462A (en) | Hangover removal drink comprising rhus verniciflua extract and preparing method thereof | |
| DE60219770T2 (en) | CANCER AGENT | |
| DE1492823A1 (en) | Process for making dairy products | |
| DE10338735B3 (en) | Process for the removal of aloin, emodin and / or iso-emodin from aloe vera | |
| DE3617368C2 (en) | Process for the preparation of a nitrogenous polysaccharide | |
| EP1560796A1 (en) | Method for purifying waste water | |
| DE102022002236A1 (en) | Hangover-free beer and its production process | |
| DE10253334A1 (en) | Purification of sewage or other substances laden with harmful organic matter and detergent or clarifying agent also useful laundry and cleaning surfaces involve introduction of photosensitizer releasing singlet oxygen when stimulated | |
| AT393772B (en) | Process for preparing a composition supplementing a foodstuff and/or feedstuff | |
| DE629449C (en) | Process for the production of organ preparations | |
| Bickis et al. | Effect of hydroxypentenal on the metabolism of normal and malignant cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |